{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:16:43Z","timestamp":1761628603448,"version":"build-2065373602"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:00:00Z","timestamp":1757116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:00:00Z","timestamp":1757116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Servier Pharmaceuticals LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s41669-025-00603-0","type":"journal-article","created":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T15:31:48Z","timestamp":1757172708000},"page":"973-984","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Estimating Health State Utilities for IDH-Mutant Diffuse Glioma"],"prefix":"10.1007","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8166-8779","authenticated-orcid":false,"given":"Ellen M.","family":"Howard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Massetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gin Nie","family":"Chua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Millie","family":"Gaydon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Savar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,6]]},"reference":[{"issue":"5","key":"603_CR1","first-page":"381","volume":"71","author":"KD Miller","year":"2021","unstructured":"Miller KD, Ostrom QT, Kruchko C, Patil N, Tihan T, Cioffi G, et al. Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin. 2021;71(5):381\u2013406.","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"603_CR2","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3390\/biomedicines8090294","volume":"8","author":"Y Liu","year":"2020","unstructured":"Liu Y, Lang F, Chou FJ, Zaghloul KA, Yang C. Isocitrate dehydrogenase mutations in glioma: genetics, biochemistry, and clinical indications. Biomedicines. 2020;8(9):294.","journal-title":"Biomedicines"},{"issue":"8","key":"603_CR3","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231\u201351.","journal-title":"Neuro Oncol"},{"issue":"1","key":"603_CR4","doi-asserted-by":"crossref","first-page":"16849","DOI":"10.1038\/s41598-021-95948-x","volume":"11","author":"S Jiang","year":"2021","unstructured":"Jiang S, Zanazzi GJ, Hassanpour S. Predicting prognosis and IDH mutation status for patients with lower-grade gliomas using whole slide images. Sci Rep. 2021;11(1):16849.","journal-title":"Sci Rep"},{"issue":"1","key":"603_CR5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/neuonc\/noac207","volume":"25","author":"JJ Miller","year":"2023","unstructured":"Miller JJ, Gonzalez Castro LN, McBrayer S, Weller M, Cloughesy T, Portnow J, et al. Isocitrate dehydrogenase (IDH) mutant gliomas: a Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro Oncol. 2023;25(1):4\u201325.","journal-title":"Neuro Oncol"},{"issue":"4","key":"603_CR6","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1200\/JCO.1997.15.4.1294","volume":"15","author":"C Leighton","year":"1997","unstructured":"Leighton C, Fisher B, Bauman G, Depiero S, Stitt L, MacDonald D, et al. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol. 1997;15(4):1294\u2013301.","journal-title":"J Clin Oncol"},{"issue":"11","key":"603_CR7","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1474-4422(05)70222-2","volume":"4","author":"R Cavaliere","year":"2005","unstructured":"Cavaliere R, Lopes MBS, Schiff D. Low-grade gliomas: an update on pathology and therapy. Lancet Neurol. 2005;4(11):760\u201370.","journal-title":"Lancet Neurol"},{"doi-asserted-by":"crossref","unstructured":"Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro Oncol. 2012 Sep 1;14(suppl 4):iv17\u201324.","key":"603_CR8","DOI":"10.1093\/neuonc\/nos161"},{"issue":"4","key":"603_CR9","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1590\/S0004-282X2011000500005","volume":"69","author":"EC Miotto","year":"2011","unstructured":"Miotto EC, Silva Junior A, Silva CC, Cabrera HN, Machado MAR, Benute GRG, et al. Cognitive impairments in patients with low grade gliomas and high grade gliomas. Arq Neuropsiquiatr. 2011;69(4):596\u2013601.","journal-title":"Arq Neuropsiquiatr"},{"issue":"3","key":"603_CR10","first-page":"255","volume":"11","author":"B Rimmer","year":"2024","unstructured":"Rimmer B, Balla M, Dutton L, Williams S, Lewis J, Gallagher P, et al. \u201cIt changes everything\u201d: understanding how people experience the impact of living with a lower-grade glioma. Neurooncol Pract. 2024;11(3):255\u201365.","journal-title":"Neurooncol Pract."},{"issue":"1","key":"603_CR11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11060-008-9738-7","volume":"92","author":"K Struik","year":"2009","unstructured":"Struik K, Klein M, Heimans JJ, Gielissen MF, Bleijenberg G, Taphoorn MJ, et al. Fatigue in low-grade glioma. J Neurooncol. 2009;92(1):73\u20138.","journal-title":"J Neurooncol"},{"issue":"9","key":"603_CR12","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/jjco\/hyaa068","volume":"50","author":"S Umezaki","year":"2020","unstructured":"Umezaki S, Shinoda Y, Mukasa A, Tanaka S, Takayanagi S, Oka H, et al. Factors associated with health-related quality of life in patients with glioma: impact of symptoms and implications for rehabilitation. Jpn J Clin Oncol. 2020;50(9):990\u20138.","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"603_CR13","first-page":"3","volume":"9","author":"SM Frances","year":"2022","unstructured":"Frances SM, Velikova G, Klein M, Short SC, Murray L, Wright JM, et al. Long-term impact of adult WHO grade II or III gliomas on health-related quality of life: a systematic review. Neurooncol Pract. 2022;9(1):3\u201317.","journal-title":"Neurooncol Pract."},{"issue":"3","key":"603_CR14","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s11136-022-03207-x","volume":"32","author":"B Rimmer","year":"2023","unstructured":"Rimmer B, Bolnykh I, Dutton L, Lewis J, Burns R, Gallagher P, et al. Health-related quality of life in adults with low-grade gliomas: a systematic review. Qual Life Res. 2023;32(3):625\u201351.","journal-title":"Qual Life Res"},{"unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: central nervous system cancers. Version 3. 2024.","key":"603_CR15"},{"issue":"3","key":"603_CR16","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","volume":"18","author":"M Weller","year":"2021","unstructured":"Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18(3):170\u201386.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"603_CR17","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1200\/JCO.21.02036","volume":"40","author":"NA Mohile","year":"2022","unstructured":"Mohile NA, Messersmith H, Gatson NT, Hottinger AF, Lassman A, Morton J, et al. Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline. J Clin Oncol. 2022;40(4):403\u201326.","journal-title":"J Clin Oncol"},{"issue":"12","key":"603_CR18","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1093\/neuonc\/noac188","volume":"24","author":"R Rud\u00e0","year":"2022","unstructured":"Rud\u00e0 R, Capper D, Waldman AD, Pallud J, Minniti G, Kaley TJ, et al. EANO-EURACAN-SNO guidelines on circumscribed astrocytic gliomas, glioneuronal, and neuronal tumors. Neuro Oncol. 2022;24(12):2015\u201334.","journal-title":"Neuro Oncol"},{"issue":"33","key":"603_CR19","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1200\/JCO.23.01059","volume":"41","author":"PY Wen","year":"2023","unstructured":"Wen PY, van den Bent M, Youssef G, Cloughesy TF, Ellingson BM, Weller M, et al. RANO 2.0: update to the response assessment in neuro-oncology criteria for high- and low-grade gliomas in adults. J Clin Oncol. 2023;41(33):5187\u201399.","journal-title":"J Clin Oncol"},{"issue":"5","key":"603_CR20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s11910-023-01265-3","volume":"23","author":"R Alshiekh Nasany","year":"2023","unstructured":"Alshiekh Nasany R, de la Fuente MI. Therapies for IDH-mutant gliomas. Curr Neurol Neurosci Rep. 2023;23(5):225\u201333.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"3","key":"603_CR21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3174\/ng.1700066","volume":"8","author":"G Barisano","year":"2018","unstructured":"Barisano G, Bergamaschi S, Acharya J, Rajamohan A, Gibbs W, Kim P, et al. Complications of radiotherapy and radiosurgery in the brain and spine. Neurographics. 2018;8(3):167\u201387.","journal-title":"Neurographics."},{"issue":"7","key":"603_CR22","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2304194","volume":"389","author":"IK Mellinghoff","year":"2023","unstructured":"Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, et al. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. New Engl J Med. 2023;389(7):589\u2013601.","journal-title":"New Engl J Med."},{"issue":"3","key":"603_CR23","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jval.2019.01.004","volume":"22","author":"J Brazier","year":"2019","unstructured":"Brazier J, Ara R, Azzabi I, Busschbach J, Chevrou-S\u00e9verac H, Crawford B, et al. Identification, review, and use of health state utilities in cost-effectiveness models: an ISPOR good practices for outcomes research task force report. Value Health. 2019;22(3):267\u201375.","journal-title":"Value Health"},{"unstructured":"National Institute for Health and Care Excellence. NICE health technology evaluations: the manual [Internet]. 2022. www.nice.org.uk\/process\/pmg36","key":"603_CR24"},{"issue":"6","key":"603_CR25","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/jnci\/djae020","volume":"116","author":"HRR Cherng","year":"2024","unstructured":"Cherng HRR, Qu M, Zafari Z, Bentzen SM, Armstrong TS, Gondi V, et al. Evaluating the sensitivity of EQ-5D-5L in patients with brain metastases: a secondary analysis of NRG CC001. J Natl Cancer Inst. 2024;116(6):983\u20139.","journal-title":"J Natl Cancer Inst"},{"key":"603_CR26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/neuonc\/noad137.011","volume":"25","author":"IK Mellinghoff","year":"2023","unstructured":"Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, et al. KS02.6.A INDIGO: a global, randomized, double-blinded, phase III study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1\/2 mutation. Neuro Oncol. 2023;25:4\u20135.","journal-title":"Neuro Oncol"},{"unstructured":"Macmillan Cancer Support. Macmillan brain cancer forum [Internet]. [cited 2025 Feb 28]. https:\/\/community.macmillan.org.uk","key":"603_CR27"},{"issue":"1","key":"603_CR28","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2648.2007.04569.x","volume":"62","author":"S Elo","year":"2008","unstructured":"Elo S, Kyng\u00e4s H. The qualitative content analysis process. J Adv Nurs. 2008;62(1):107\u201315.","journal-title":"J Adv Nurs"},{"unstructured":"Prolific. Prolific [Internet]. London, UK: Prolific; 2014. https:\/\/www.prolific.com. Accessed 28 Feb 2025.","key":"603_CR29"},{"unstructured":"Office for National Statistics. 2011 Census data [Internet]. https:\/\/www.ons.gov.uk\/census\/2011census. Accessed 28 Feb 2025.","key":"603_CR30"},{"unstructured":"Qualtrics. Qualtrics XM platform TM. Provo, Utah, USA; 2024.","key":"603_CR31"},{"issue":"2","key":"603_CR32","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40273-022-01218-7","volume":"41","author":"M Hern\u00e1ndez Alava","year":"2023","unstructured":"Hern\u00e1ndez Alava M, Pudney S, Wailoo A. Estimating the relationship between EQ-5D-5L and EQ-5D-3L: results from a UK population study. Pharmacoeconomics. 2023;41(2):199\u2013207.","journal-title":"Pharmacoeconomics"},{"unstructured":"Morton F, Singh Nijar J. Package \u201ceq5d\u201d\u2014methods for analysing \u201cEQ-5D\u201d data and calculating \u201cEQ-5D\u201d index scores [Internet]. 2025. https:\/\/cran.r-project.org\/web\/packages\/eq5d\/eq5d.pdf. Accessed 28 Feb 2025.","key":"603_CR33"},{"unstructured":"The University of Sheffield. NICE Decision Support Unit [Internet]. https:\/\/www.sheffield.ac.uk\/nice-dsu. Accessed 28 Feb 2025.","key":"603_CR34"},{"issue":"5","key":"603_CR35","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1524-4733.2010.00700.x","volume":"13","author":"R Ara","year":"2010","unstructured":"Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. Value Health. 2010;13(5):509\u201318.","journal-title":"Value Health"},{"issue":"4","key":"603_CR36","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jval.2018.09.2843","volume":"22","author":"AJ Thompson","year":"2019","unstructured":"Thompson AJ, Sutton M, Payne K. Estimating joint health condition utility values. Value Health. 2019;22(4):482\u201390.","journal-title":"Value Health"},{"issue":"11","key":"603_CR37","first-page":"2965","volume":"22","author":"N Gregg","year":"2014","unstructured":"Gregg N, Arber A, Ashkan K, Brazil L, Bhangoo R, Beaney R, et al. Neurobehavioural changes in patients following brain tumour: patients and relatives perspective. Support Care Cancer. 2014;22(11):2965\u201372.","journal-title":"Support Care Cancer"},{"issue":"3","key":"603_CR38","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11060-006-9280-4","volume":"82","author":"N Pouratian","year":"2007","unstructured":"Pouratian N, Gasco J, Sherman JH, Shaffrey ME, Schiff D. Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. J Neurooncol. 2007;82(3):281\u20138.","journal-title":"J Neurooncol"},{"key":"603_CR39","first-page":"11","volume":"20","author":"A Leonetti","year":"2021","unstructured":"Leonetti A, Puglisi G, Rossi M, Vigan\u00f2 L, Conti Nibali M, Gay L, et al. Factors influencing mood disorders and health related quality of life in adults with glioma: a longitudinal study. Front Oncol. 2021;20:11.","journal-title":"Front Oncol"},{"issue":"5","key":"603_CR40","doi-asserted-by":"crossref","first-page":"E120","DOI":"10.1188\/20.ONF.E120-E130","volume":"47","author":"M Li","year":"2020","unstructured":"Li M, Shi Q, Yan L, Tian L, Li H, Lu J, et al. A qualitative systematic review of the experiences and needs of patients with gliomas. Oncol Nurs Forum. 2020;47(5):E120\u201330.","journal-title":"Oncol Nurs Forum"},{"issue":"23","key":"603_CR41","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1002\/cncr.34980","volume":"129","author":"AE Heffernan","year":"2023","unstructured":"Heffernan AE, Wu Y, Benz LS, Verhaak RGW, Kwan BM, Claus EB. Quality of life after surgery for lower grade gliomas. Cancer. 2023;129(23):3761\u201371.","journal-title":"Cancer"},{"issue":"12","key":"603_CR42","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/neuonc\/not109","volume":"15","author":"R Ruda","year":"2013","unstructured":"Ruda R, Magliola U, Bertero L, Trevisan E, Bosa C, Mantovani C, et al. Seizure control following radiotherapy in patients with diffuse gliomas: a retrospective study. Neuro Oncol. 2013;15(12):1739\u201349.","journal-title":"Neuro Oncol"},{"issue":"12","key":"603_CR43","first-page":"1205","volume":"14","author":"M Gustafsson","year":"2006","unstructured":"Gustafsson M, Edvardsson T, Ahlstr\u00f6m G. The relationship between function, quality of life and coping in patients with low-grade gliomas. Support Care Cancer. 2006;14(12):1205\u201312.","journal-title":"Support Care Cancer"},{"issue":"10","key":"603_CR44","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/jjco\/hyv115","volume":"45","author":"Y Okita","year":"2015","unstructured":"Okita Y, Narita Y, Miyahara R, Miyakita Y, Ohno M, Shibui S. Health-related quality of life in long-term survivors with grade II gliomas: the contribution of disease recurrence and Karnofsky Performance Status. Jpn J Clin Oncol. 2015;45(10):906\u201313.","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"603_CR45","first-page":"847","volume":"22","author":"EM Sizoo","year":"2014","unstructured":"Sizoo EM, Pasman HRW, Dirven L, Marosi C, Grisold W, Stockhammer G, et al. The end-of-life phase of high-grade glioma patients: a systematic review. Support Care Cancer. 2014;22(3):847\u201357 (Mar 14;).","journal-title":"Support Care Cancer"},{"issue":"3","key":"603_CR46","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s11060-009-9939-8","volume":"95","author":"A Budrukkar","year":"2009","unstructured":"Budrukkar A, Jalali R, Dutta D, Sarin R, Devlekar R, Parab S, et al. Prospective assessment of quality of life in adult patients with primary brain tumors in routine neurooncology practice. J Neurooncol. 2009;95(3):413\u20139.","journal-title":"J Neurooncol"},{"issue":"4","key":"603_CR47","first-page":"222","volume":"3","author":"H Zwinkels","year":"2016","unstructured":"Zwinkels H, Dirven L, Vissers T, Habets EJJ, Vos MJ, Reijneveld JC, et al. Prevalence of changes in personality and behavior in adult glioma patients: a systematic review. Neurooncol Pract. 2016;3(4):222\u201331.","journal-title":"Neurooncol Pract."},{"issue":"5","key":"603_CR48","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/jnnp.55.5.372","volume":"55","author":"MJ Taphoorn","year":"1992","unstructured":"Taphoorn MJ, Heimans JJ, Snoek FJ, Lindeboom J, Oosterink B, Wolbers JG, et al. Assessment of quality of life in patients treated for low-grade glioma: a preliminary report. J Neurol Neurosurg Psychiatry. 1992;55(5):372\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"603_CR49","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S1474-4422(09)70204-2","volume":"8","author":"L Douw","year":"2009","unstructured":"Douw L, Klein M, Fagel SS, van den Heuvel J, Taphoorn MJ, Aaronson NK, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009;8(9):810\u20138.","journal-title":"Lancet Neurol"},{"issue":"1","key":"603_CR50","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1212\/WNL.59.1.40","volume":"59","author":"CL Armstrong","year":"2002","unstructured":"Armstrong CL, Hunter JV, Ledakis GE, Cohen B, Tallent EM, Goldstein BH, et al. Late cognitive and radiographic changes related to radiotherapy. Neurology. 2002;59(1):40\u20138.","journal-title":"Neurology"},{"issue":"7","key":"603_CR51","doi-asserted-by":"crossref","first-page":"e856","DOI":"10.1212\/WNL.0000000000009982","volume":"95","author":"I Ryd\u00e9n","year":"2020","unstructured":"Ryd\u00e9n I, Carstam L, Gulati S, Smits A, Sunnerhagen KS, Hellstr\u00f6m P, et al. Return to work following diagnosis of low-grade glioma. Neurology. 2020;95(7):e856\u201366.","journal-title":"Neurology"},{"key":"603_CR52","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1016\/j.wneu.2018.06.052","volume":"117","author":"C Drewes","year":"2018","unstructured":"Drewes C, Sagberg LM, Jakola AS, Solheim O. Perioperative and postoperative quality of life in patients with glioma\u2014a longitudinal cohort study. World Neurosurg. 2018;117:e465\u201374.","journal-title":"World Neurosurg."},{"issue":"2","key":"603_CR53","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s11060-023-04419-y","volume":"164","author":"M Pertz","year":"2023","unstructured":"Pertz M, Schl\u00f6mer S, Seidel C, Hentschel B, L\u00f6ffler M, Schackert G, et al. Long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up. J Neurooncol. 2023;164(2):353\u201366.","journal-title":"J Neurooncol"},{"issue":"16","key":"603_CR54","doi-asserted-by":"crossref","first-page":"e14039","DOI":"10.1200\/JCO.2024.42.16_suppl.e14039","volume":"42","author":"D Bhanja","year":"2024","unstructured":"Bhanja D, Wilding H, Tuohy K, Ozair A, Hamidi N, Filho L, et al. Health state utility assessment for low-grade glioma. J Clin Oncol. 2024;42(16):e14039.","journal-title":"J Clin Oncol"},{"issue":"1","key":"603_CR55","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1080\/13696998.2023.2176678","volume":"26","author":"HM de Freitas","year":"2023","unstructured":"de Freitas HM, Danese D, Hubig L, Lloyd A, Lombardelli S. Estimating health state utilities in primary hyperoxaluria type 1: a valuation study. J Med Econ. 2023;26(1):386\u201393.","journal-title":"J Med Econ"},{"issue":"6","key":"603_CR56","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3233\/JND-210686","volume":"8","author":"A Lloyd","year":"2021","unstructured":"Lloyd A, Aggio D, Slocomb TL, Lee J, Beggs AH, Bilder DA. Estimation of the quality-of-life impact of X-linked myotubular myopathy. J Neuromuscul Dis. 2021;8(6):1047\u201361.","journal-title":"J Neuromuscul Dis."},{"issue":"1","key":"603_CR57","doi-asserted-by":"crossref","first-page":"41","DOI":"10.36469\/jheor.2023.68157","volume":"10","author":"L Hubig","year":"2023","unstructured":"Hubig L, Sussex AK, MacCulloch A, Hughes D, Graham R, Morris L, et al. Quality of life with late-onset Pompe disease: qualitative interviews and general public utility estimation in the United Kingdom. J Health Econ Outcomes Res. 2023;10(1):41.","journal-title":"J Health Econ Outcomes Res."},{"issue":"4","key":"603_CR58","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s11136-021-03026-6","volume":"31","author":"TM Hansen","year":"2022","unstructured":"Hansen TM, Stavem K, Rand K. Time trade-off with someone to live for: impact of having significant others on time trade-off valuations of hypothetical health states. Qual Life Res. 2022;31(4):1199\u2013207.","journal-title":"Qual Life Res"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00603-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-025-00603-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00603-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:12:59Z","timestamp":1761628379000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-025-00603-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,6]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["603"],"URL":"https:\/\/doi.org\/10.1007\/s41669-025-00603-0","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"type":"print","value":"2509-4262"},{"type":"electronic","value":"2509-4254"}],"subject":[],"published":{"date-parts":[[2025,9,6]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was funded by Servier Pharmaceuticals LLC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ellen M. Howard, Gin Nie Chua, Millie Gaydon and Sara Savar are employees of Acaster Lloyd Consulting Ltd. Andrew Lloyd is an employee and shareholder of Acaster Lloyd Consulting Ltd. Acaster Lloyd Consulting Ltd were commissioned by Servier Pharmaceuticals LLC, the study sponsor, to conduct the study. Marc Massetti is an employee of Servier Pharmaceuticals LLC.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ellen M. Howard: investigation, methodology, formal analysis, project administration, writing\u2014original draft, writing\u2014review and editing and visualisation. Millie Gaydon: investigation, methodology, formal analysis, project administration and writing\u2014original draft. Sara Savar: investigation, methodology, formal analysis, project administration and writing\u2014original draft. Marc Massetti: conceptualisation, methodology and writing\u2014review and editing. Andrew Lloyd: conceptualisation, methodology and writing\u2014review and editing. Gin Nie Chua: conceptualisation, investigation, methodology, formal analysis, project administration, writing\u2014original draft, writing\u2014review and editing, visualisation and validation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions:"}},{"value":"This study was conducted in compliance with the Declaration of Helsinki. Study materials were reviewed and deemed exempt by an institutional review board (Western Institutional Review Board [WIRB], IRB no.: 20241559).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all participants prior to their involvement in the study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Informed consent for publication was obtained from all participants prior to their involvement in the study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data that support the findings of this study are not publicly available, as they are proprietary to the study sponsor.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not available.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}